Fundraising FoxBugworks Research
Wilmington, US · Founded 2014 · Delaware corporation · 9 known investors
Find your way into Bugworks Research
Sign up to see every warm intro you have to Bugworks Research
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bugworks Research team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Bugworks Research is a drug discovery company developing small molecule therapeutics, including novel antibacterial agents targeting antimicrobial resistance (AMR) across Gram-negative and Gram-positive infections and next-generation immuno-oncology treatments for hard-to-treat tumors. Its research focuses on affordable oral and intravenous therapies for serious hospital and community infections and cancer.
Founders & leadership
Bugworks Research was founded in 2014 by Anand Anandkumar.
AA
Anand AnandkumarFounder and CEOAnand Anandkumar is co-founder and CEO of Bugworks Research, a drug discovery company developing antibacterial and immuno-oncology therapeutics. He has over 35 years of experience spanning semiconductor, electronic design automation, biotech, and pharmaceutical industries.
Investors · 9
3one4 Capitallisted by 3one4 CapitalBengaluru
How we know: 3one4 Capital's portfolio page · Not right? Tell us
Global Brainlisted by Global BrainTokyo · $100K
How we know: funding news · economictimes.indiatimes.com · globalbrains.com · Not right? Tell us
Also in the syndicate · 7
3ONE4Capital3ONE4Capital IndiaAcquipharma Holdings S.AFeatherlite Group IndiaI.M Holdings B.V.Lightrock IndialeadThe University of Tokyo Edge Capital (UTEC) Japan
Reported raises · per SEC filings
Form D private placements$39.1M disclosed across 5 rounds · 2015–2024
▶$6.8MraisedMar 2024 · 15 investors · BiotechnologyRule 506(b)
▶$6.8MraisedMar 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pradeep FernandesExecutive Officer
- Santanu DattaDirector
- Anand AnandkumarExecutive Officer, Director
- Tejasvi RaviDirector
- Atsushi UsamiDirector
- Venkataraman SubramanianDirector
- Offering amount
- $15.8M
- Amount sold
- $6.8M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16MraisedDec 2021 · 19 investors · BiotechnologyRule 506(b)
▶$16MraisedDec 2021 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bala SubramanianExecutive Officer, Director
- Pradeep FernandesExecutive Officer
- Santanu DattaExecutive Officer, Director
- Atsushi UsamiDirector
- Anand AnandkumarExecutive Officer, Director
- Tejasvi RaviDirector
- Offering amount
- $19.4M
- Amount sold
- $16M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.2MraisedNov 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$6.2MraisedNov 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anand AnandkumarExecutive Officer, Director
- Santanu DattaExecutive Officer, Director
- Pradeep FernandesExecutive Officer
- Bala SubramanianExecutive Officer, Director
- Atsushi UsamiDirector
- Offering amount
- $6.2M
- Amount sold
- $6.2M
- Minimum investment
- $250K
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5MraisedAug 2018 · 13 investors · Other TechnologyRule 506(b)
▶$8.5MraisedAug 2018 · 13 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Atushi UsamiDirector
- Anand AnandkumarExecutive Officer, Director
- Pradeep FernandesExecutive Officer
- Bala SubramanianDirector
- Santanu DattaDirector
- Offering amount
- $9.2M
- Amount sold
- $8.5M
- Minimum investment
- $95.8K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1.6MraisedNov 2015 · 7 investors · Other TechnologyRule 506(b)
▶$1.6MraisedNov 2015 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Anand AnandkumarExecutive Officer
- Offering amount
- $2.3M
- Amount sold
- $1.6M
- Minimum investment
- $26.5K
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
ZymeworksZymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D. It operates as a royalty-driven organization that builds and manages a portfolio of healthcare assets through partnerships and collaborations across multiple therapeutic areas.
SpringworkstxSpringWorks is a biotechnology company focused on developing innovative treatments for cancer patients. The company combines rigorous scientific research with an operational commitment to rapidly advance therapeutic solutions.
Companies working in the same space as Bugworks Research.
In the news
Frequently asked questions
- What does Bugworks Research do?
- Bugworks Research is a drug discovery company developing small molecule therapeutics, including novel antibacterial agents targeting antimicrobial resistance (AMR) across Gram-negative and Gram-positive infections and next-generation immuno-oncology treatments for hard-to-treat tumors. Its research focuses on affordable oral and intravenous therapies for serious hospital and community infections and cancer.
- Who founded Bugworks Research?
- Bugworks Research was founded by Anand Anandkumar in 2014.
- Who are Bugworks Research's investors?
- Bugworks Research's investors include 3one4 Capital, Global Brain.
- How much funding has Bugworks Research raised?
- Bugworks Research has disclosed $39.1M raised across 5 rounds.
- Where is Bugworks Research headquartered?
- Bugworks Research is headquartered in Wilmington, US.